Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.82 |
| ▸ | CLK2 | P49760 | 11/20 | 0.82 |
| ▸ | CLK3 | P49761 | 11/20 | 0.82 |
| ▸ | WNT1 | P04628 | 13/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160677 | 0.98 | DYRK1A (0.79) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792561 | 0.95 | DYRK1A (0.87) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095929 | 0.95 | DYRK1A (0.88) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792761 | 0.95 | DYRK1A (0.88) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792646 | 0.94 | DYRK1A (0.84) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792626 | 0.93 | DYRK1A (0.83) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL18160663 | 0.93 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14782169 | 0.93 | DYRK1A (0.85) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095618 | 0.93 | DYRK1A (0.85) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL18160652 | 0.93 | DYRK1A (0.70) | DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304488-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-10-20 | — | — | US | disclosed |
| US-20160304488-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304488-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | DYRK1A 733/4885CLK2 1021/4885CLK3 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.